VLA Valneva SE

2.597USD2.363 EUR · EPA-3.55%Mkt Cap: 494.17M USDP/E: —

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese ence…

Institutional holders9 on file

Key Statistics

Company
Market Cap494.17M USD
Enterprise Value590.10M USD
Revenue (TTM)157.12M USD
Gross Profit74.22M USD
Net Income (TTM)-126.62M USD
Revenue/Share0.88 USD
Last Price2.597 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees620
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0004056851
Valuation
P/E (Trailing)—
P/E (Forward)15.34
PEG-13.06
EV/EBITDA-5.44
EV/Revenue3.76
P/S3.15
P/B5.52
EPS (TTM)-0.99 USD
EPS (Forward)0.17 USD
52W Range
2.23511% of range5.661
52W High5.661 USD
52W Low2.235 USD
Profitability
Gross Margin38.66%
Oper. Margin-80.38%
EBITDA Margin-69.07%
Profit Margin-65.95%
ROE-108.50%
ROA-28.88%
ROIC-40.06%
ROCE-26.72%
Growth
Revenue Growth-27.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-58.14M USD
CapEx (TTM)4.93M USD
FCF Margin-29.73%
FCF Yield-9.45%
Net Debt97.50M USD
Net Debt/EBITDA-0.90
Net Debt/FCF—
Balance Sheet
Debt/Equity1.95
Current Ratio2.16
Quick Ratio1.33
Book Value/Sh0.47 USD
Cash/Share0.70 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.815 USD
Upside (mean)+162.4%
Target Range2.418 USD – 13.19 USD
2.418+162.4% to mean13.19
# Analysts7
Ownership
Shares Out.190.26M
Float171.41M
Insiders10.69%
Institutions23.28%
Technical
SMA 502.866 (-9.4%)
SMA 2003.096 (-16.1%)
Beta1.45
S&P 52W Chg8.68%
Avg Vol (30d)397.80K
Avg Vol (10d)449.44K
Technical Indicators
RSI (14)39.5
MACD-0.0245
MACD Signal-0.0121
MACD Hist.-0.0125
BB Upper2.956 USD
BB Middle2.769 USD
BB Lower2.581 USD
BB Width13.55%
ATR (14)0.1208 USD
Vol Ratio (20d)1.08x

About Valneva (EPA: VLA)

›

Valneva (EPA: VLA) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 620 employees.

The shares were at 2.363 EUR on 20 November 2026, down 37.8% over 52 weeks. Its 52-week range is 2.033 EUR to 5.150 EUR: the price is 54.1% below the high and 16.2% above the low.

Its market capitalisation is 449.57M EUR.

Valneva reports return on equity of -108.5%, an operating margin of -80.4% and revenue down 27.7% year over year.

Its debt exceeds its cash by 88.71M EUR, a debt-to-equity ratio of 1.95. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Buy; their mean price target of 6.200 EUR is 162.4% above the current price. The next earnings report is expected on 17 March 2027.